Briana Contreras

Ruxolitinib cream shows promising results in repigmenting vitiligo lesions, enhancing skin appearance and quality of life with a strong safety profile.

Research reveals that even with over 25 million losing Medicaid during unwinding in 2023, the uninsured rate remains stable as many quickly re-enroll or switch coverage.

A study revealed that the 2024-2025 COVID-19 vaccine significantly reduces emergency visits, hospitalizations and deaths among U.S. veterans.

Experts discuss the implications of Most Favored Nation pricing on U.S. drug costs, innovation and patient access in the latest MJH Life Sciences webinar.

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved outcomes post-surgery and radiation.

The CDC updates vaccine schedules, emphasizing personalized decision-making for COVID-19 shots and recommending standalone chickenpox vaccines for toddlers.

Medicare beneficiaries face confusion during the Annual Enrollment Period, with significant plan changes ahead for 2026. Understanding options is crucial.

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, steroid-free solution.

A new study confirms ICD-10 code L80's high accuracy in identifying vitiligo, especially when combined with treatment data, enhancing clinical research.

Humana announces its 2026 Medicare Advantage and prescription drug plans, focusing on stable benefits, preventive care and enhanced member support.

UnitedHealthcare reveals its 2026 Medicare Advantage plans, featuring $0 premiums, expanded benefits and enhanced access to affordable healthcare options.

In this conversation with Kristin Begley, chief commercial officer at Capital Rx, we discussed the company’s recent rebrand to Judi Health and how it reflects broader trends in technology-driven, transparent PBMs.

Changes in eye blood vessels signal early risk for Alzheimer’s disease, offering a noninvasive biomarker for early detection and intervention.

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing patient access and competition.

Recent analysis reveals Medicaid's impact on mortality, highlighting the need for diverse research methods to inform policy changes effectively.

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing uncompensated care costs.

MedImpact launches a performance-driven PMPM pricing model, enhancing cost predictability and accountability for health plans amid rising pharmacy expenses.

FDA rejects Rexulti's approval for PTSD treatment, citing insufficient evidence of effectiveness in combination with sertraline. Otsuka and Lundbeck announced they are planning next steps.

Judi Health redefines health benefit management with a $400 million funding boost, enhancing transparency and efficiency for employers and health plans.

Carbapenemase-producing Enterobacterales (CRE) surge in the U.S., with New Delhi metallo-β-lactamase (NDM) becoming a major public health threat.

Employers adapt healthcare strategies amid rising costs, focusing on specialty drugs and chronic conditions to enhance employee wellbeing and control expenses.

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster administration and broader access to immunotherapy.

Opzelura gains FDA approval as the first topical JAK inhibitor for children with atopic dermatitis, offering a steroid-free treatment option.

The Advisory Committee on Immunization Practices pulled back its recommendation concerning a shot that combines the measles, mumps and rubella vaccine with one for varicella. A vote on the hepatitis B vaccine at birth was postponed until tomorrow.

ACIP's upcoming meeting addresses vital vaccine updates, including COVID-19 and MMRV, while introducing new members to enhance public health transparency.

Povorcitinib shows promising results for hidradenitis suppurativa, offering significant lesion reduction and pain relief in recent phase 3 trials.

Parents express mixed feelings about COVID-19 vaccines, revealing a significant divide in trust and safety perceptions, according to a KFF survey analysis.

A recent study revealed that hidradenitis suppurativa affects 1% of the global population, highlighting significant gender disparities and the need for further research.

Jennifer Walsh of George Washington University’s School of Nursing warned that limiting COVID-19 vaccine approvals to older adults and high-risk groups could heighten disparities, reduce access and leave vulnerable populations at greater risk of infection and severe outcomes.

Discover groundbreaking research on hard-to-treat skin conditions like hidradenitis suppurativa and vitiligo at the EADV 2025 Congress in Paris.